Viridian Data Lift Prospects for Thyroid Eye Disease Drug

Why It Matters

The data clears a regulatory hurdle and strengthens Viridian’s bid to challenge Amgen’s market‑dominant Tepezza, potentially expanding treatment options and reshaping the $2 billion thyroid eye disease market.

Key Takeaways

• Elegrobart achieved 50-54% response in chronic thyroid eye disease.
• Placebo response was only 15%, showing statistical significance.
• Double‑vision improvement reached 61% with monthly dose.
• Side effects were mild; hearing loss rates low.
• Shares jumped ~30% after results, boosting investor confidence.

Pulse Analysis

Thyroid eye disease (TED) remains a niche yet lucrative segment of ophthalmology, with Amgen’s Tepezza accounting for roughly $2 billion in annual sales. The injectable’s success has spurred a wave of IGF‑1R antagonists, as clinicians seek alternatives that reduce infusion burden and mitigate side‑effects like hearing loss. Viridian’s elegrobart, delivered via a simple under‑the‑skin injection, directly addresses these unmet needs, offering a patient‑friendly at‑home option that could broaden market penetration beyond specialty infusion centers.

In the REVEAL2 Phase 3 trial, elegrobart’s once‑monthly and bi‑monthly dosing achieved response rates of 50% and 54% after 24 weeks, dramatically outpacing the 15% placebo benchmark. The drug also demonstrated a notable 61% improvement in diplopia for the monthly cohort, although the longer‑interval regimen fell short of statistical significance for that endpoint. Safety data were reassuring: adverse events were predominantly mild, and the incidence of hearing impairment—an issue linked to Tepezza—remained low. With a projected regulatory filing in Q1 2027, elegrobart could enter the market before Viridian’s IV candidate veligrotug, potentially securing first‑to‑market advantage in the subcutaneous space.

Investors reacted positively, propelling Viridian’s stock up roughly 30% as analysts cited the results as “highly competitive” and the strongest chronic subcutaneous dataset to date. The trial’s success not only revitalizes confidence in Viridian’s pipeline but also intensifies competition for Amgen, which is concurrently testing a subcutaneous Tepezza formulation. Should elegrobart receive approval, patients would gain a convenient, home‑administered therapy, and the competitive pressure could drive pricing and innovation across the TED treatment landscape.